116 related articles for article (PubMed ID: 25518357)
1. [Treatment sequence using newly developed agents for men with castration resistant prostate cancer].
Fujimoto N
Nihon Rinsho; 2014 Dec; 72(12):2193-7. PubMed ID: 25518357
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy for CRPC].
Ozono S; Furuse H
Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
[TBL] [Abstract][Full Text] [Related]
3. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
4. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
5. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
6. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
Zustovich F; Fabiani F
Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
Pinto A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
[TBL] [Abstract][Full Text] [Related]
9. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
[TBL] [Abstract][Full Text] [Related]
10. Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?
Mottet N; Clarke N; De Santis M; Zattoni F; Morote J; Joniau S
BJU Int; 2015 Mar; 115(3):364-72. PubMed ID: 24628790
[TBL] [Abstract][Full Text] [Related]
11. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Biol Ther; 2014 Jan; 14(1):7-10. PubMed ID: 24074253
[TBL] [Abstract][Full Text] [Related]
12. [Roles of medical oncologists in the new era of CRPC therapy in Japan].
Takahashi S
Gan To Kagaku Ryoho; 2014 Jul; 41(7):827-31. PubMed ID: 25131868
[TBL] [Abstract][Full Text] [Related]
13. Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era.
Hoshi S; Numahata K; Ono K; Yasuno N; Bilim V; Hoshi K; Amemiya H; Sasagawa I; Ohta S
Mol Clin Oncol; 2017 Oct; 7(4):601-603. PubMed ID: 28855993
[TBL] [Abstract][Full Text] [Related]
14. [New era of the treatment of CRPC in Japan].
Akaza H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
[TBL] [Abstract][Full Text] [Related]
15. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
16. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
17. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
19. The economics of abiraterone acetate for castration-resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):175-9. PubMed ID: 24564607
[TBL] [Abstract][Full Text] [Related]
20. Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?
Dogan M; Erdem GU; Zengin N
Asian Pac J Cancer Prev; 2015; 16(14):6167-9. PubMed ID: 26320514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]